Skip to main content

Table 2 Toxicity possibly, probably, or definitely attributable to chemotherapy (n = 51)

From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Adverse events

Grade 1

Grade 2

Grade 3

Grade 4

Total

No. of patients

(%)

No. of patients

(%)

No. of patients

(%)

No. of patients

(%)

No. of patients

(%)

Hematological

 Leucopenia

15

29.4

17

33.3

1

1.96

1

1.96

34

66.7

 Neutropenia

13

25.5

13

25.5

5

9.8

2

3.9

33

64.7

 Anemia

12

23.5

10

19.6

3

5.9

0

0

25

49.0

 Thrombocytopenia

7

13.7

11

21.6

7

13.7

4

7.8

29

56.9

Non-hematological

 Hepatic dysfunction

19

37.3

3

5.9

1

1.9

0

0

23

45.1

 Nausea/vomiting

15

29.3

11

21.6

2

3.9

0

0

28

54.9

 Neurotoxicity

12

23.5

3

5.9

2

3.9

0

0

17

13.7

 Hand-food syndrome

12

23.5

5

9.8

2

3.9

0

0

19

37.3

 Anorexia

8

15.7

0

0

1

1.9

0

0

9

17.6

 Diarrhea

5

9.8

4

7.8

2

3.9

0

0

11

21.6

 Infusion reaction

3

5.9

2

3.9

0

0

0

0

5

9.8

 Fatigue

1

1.9

3

5.9

1

1.9

0

0

5

9.8

 Arrhythmia

2

3.9

3

5.9

0

0

0

0

5

9.8